Ian E. Krop

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract 1222: Spatial transcriptomics of trastuzumab deruxtecan-treated metastatic breast cancer identifies candidate response and resistance factors.

  Cancer Research · 2026-04-03

• Abstract 1220: Spatial transcriptomics revealed potential resistance and response factors of sacituzumab govitecan in metastatic breast cancer.

  Cancer Research · 2026-04-03

• CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy

  Journal of the National Comprehensive Cancer Network · 2026-03-27

• Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results

  Nature Cancer · 2026-03-18 · 1 citations

• Supplementary Figure S4 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S3 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Table S1 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Data from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S11 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S6 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S5 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Table S2 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S2 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Table S4 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Table S5 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S9 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S10 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S1 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S13 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S12 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i>-Mutated Solid Tumors and in Preclinical Models

  2026-01-06